D-serine in Schizophrenia

• Conditions: Schizophrenia
• Interventions: Dietary Supplement: D-serine

• Registration Number: NCT03702933
• Lead Sponsor: Herzog Hospital

Brief Summary

This study will assess the effects of D-serine adjuvant treatment to the ongoing pharmacological treatment of schizophrenia patients that are resistant to treatments.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-09-01
• Status Verified: 2018-10
• Study First Submitted: 2018-10-09
• Study First Submitted QC: 2018-10-09
• Last Update Submitted: 2018-10-09
• Study First Posted: 2018-10-11
• Last Update Posted: 2018-10-11
• Primary Completion: 2021-09-01
• Study Completion: 2021-12-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• DSM-5 Schizophrenia criteria, able and willing to give informed consent, and comply to study procedure, adequate contraception, post-menopausal or abstinent, PANSS Total Score equal or greater than 70, score of 4 or greater on two psychotic items

Exclusion Criteria

• clinically significant, uncontrollable or unstable medical condition, mental retardation or severe organic brain syndrome, significant risk of suicide or violent behavior

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
High Dose	D-serine	3.5 g/d D-serine adjuvant treatment
Low Dose	D-serine	2.1 g/d D-serine adjuvant treatment
Placebo	D-serine	starch

Primary Outcome Measures

Name	Time	Method
PANSS Total Score	6 weeks

Trial Locations

Locations (1)

Herzog Hospital; 🇮🇱 Jerusalem, Israel